BALAXIPharmaceuticals
Balaxi Pharmaceuticals Ltd — Cash Flow Statement
₹15.67
-9.20%
Balaxi Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Other Financing Charges | 0.09 Cr | 0.04 Cr | -2000.00 | -1000.00 | — |
| Interest Paid Cff | -2.78 Cr | -1.53 Cr | -0.35 Cr | -0.14 Cr | — |
| Net Common Stock Issuance | 2.70 Cr | 25.79 Cr | 18.47 Cr | 0.00 | — |
| Common Stock Issuance | 2.70 Cr | 25.79 Cr | 18.47 Cr | 0.00 | — |
| Net Issuance Payments Of Debt | 33.96 Cr | 6.04 Cr | 7.98 Cr | -0.02 Cr | — |
| Net Long Term Debt Issuance | 33.96 Cr | 6.04 Cr | 7.98 Cr | -0.02 Cr | — |
| Long Term Debt Issuance | 33.96 Cr | 6.04 Cr | 7.98 Cr | — | 3.66 Cr |
| Investing Cash Flow | -21.76 Cr | -1.05 Cr | -10.57 Cr | -28.45 Cr | — |
| Net Investment Purchase And Sale | 0.00 | 0.00 | 0.00 | 3.42 Cr | — |
| Sale Of Investment | 0.00 | 0.00 | 0.00 | 3.42 Cr | — |
| Purchase Of Investment | 0.00 | 0.00 | 0.00 | — | -3.42 Cr |
| Net Intangibles Purchase And Sale | -0.64 Cr | -0.88 Cr | -1.92 Cr | -22.02 Cr | — |
| Purchase Of Intangibles | -0.64 Cr | -0.88 Cr | -1.92 Cr | -22.02 Cr | — |
| Net PPE Purchase And Sale | -21.12 Cr | -0.17 Cr | -10.80 Cr | -4.75 Cr | — |
| Purchase Of PPE | -21.12 Cr | -0.69 Cr | -10.80 Cr | -4.75 Cr | — |
| Operating Cash Flow | -35.00 Cr | 4.87 Cr | 6.08 Cr | 34.14 Cr | — |
| Taxes Refund Paid | -3.21 Cr | -6.68 Cr | -12.09 Cr | -5.59 Cr | — |
| Change In Working Capital | -67.89 Cr | 10.68 Cr | -46.79 Cr | -15.97 Cr | — |
| Change In Other Current Liabilities | -83000.00 | 1.81 Cr | 0.76 Cr | -0.05 Cr | — |
| Change In Other Current Assets | -2.88 Cr | -1.77 Cr | -0.49 Cr | -3.02 Cr | — |
| Change In Payable | -12.86 Cr | -5.48 Cr | -15.81 Cr | 27.41 Cr | — |
| Change In Prepaid Assets | -1.21 Cr | -0.25 Cr | 0.13 Cr | -1.73 Cr | — |
| Change In Inventory | 3.69 Cr | 22.86 Cr | -6.32 Cr | -85.09 Cr | — |
| Change In Receivables | -54.63 Cr | -6.49 Cr | -25.05 Cr | 46.51 Cr | — |
| Other Non Cash Items | 5.53 Cr | -3.24 Cr | 6.28 Cr | 0.67 Cr | — |
| Depreciation And Amortization | 1.89 Cr | 2.10 Cr | 1.75 Cr | 0.51 Cr | — |
| Depreciation | 1.89 Cr | 2.10 Cr | 1.75 Cr | 0.51 Cr | — |
| Net Income From Continuing Operations | 28.67 Cr | 2.02 Cr | 56.92 Cr | 54.52 Cr | — |
| Free Cash Flow | -56.77 Cr | 3.30 Cr | -8.90 Cr | 6.80 Cr | — |
| Issuance Of Debt | 33.96 Cr | 6.04 Cr | 7.98 Cr | — | 3.66 Cr |
| Issuance Of Capital Stock | 2.70 Cr | 25.79 Cr | 18.47 Cr | 0.00 | — |
| Capital Expenditure | -21.76 Cr | -1.57 Cr | -14.98 Cr | -27.34 Cr | — |
| End Cash Position | 39.40 Cr | 62.29 Cr | 28.21 Cr | 7.19 Cr | — |
| Beginning Cash Position | 62.29 Cr | 28.21 Cr | 7.19 Cr | 1.66 Cr | — |
| Changes In Cash | -22.89 Cr | 34.07 Cr | 21.02 Cr | 5.53 Cr | — |
| Financing Cash Flow | 33.88 Cr | 30.25 Cr | 25.51 Cr | -0.16 Cr | — |
| Net Other Investing Changes | — | -1000.00 | -0.06 Cr | -0.05 Cr | — |
| Sale Of PPE | — | 0.52 Cr | — | — | — |
| Other Cash Adjustment Outside Changein Cash | — | 1000.00 | 1000.00 | -1000.00 | 1000.00 |
| Cash Dividends Paid | — | — | -0.50 Cr | — | — |
| Capital Expenditure Reported | — | — | -2.26 Cr | -0.57 Cr | 0.00 |
| Net Preferred Stock Issuance | — | — | — | 0.00 | 0.00 |
| Preferred Stock Issuance | — | — | — | 0.00 | 0.00 |
| Long Term Debt Payments | — | — | — | -0.02 Cr | 0.00 |
| Repayment Of Debt | — | — | — | -0.02 Cr | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Balaxi Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.